Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Preoperative Capecitabine, Oxaliplatin, Cetuximab, and Radiation Therapy for Locally Advanced Esophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 8
- Registration Number
- NCT00430027
- Locations
- 🇺🇸
University of Colorado at Denver and Health Science Center, Aurora, Colorado, United States
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2009-05-29
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 272
- Registration Number
- NCT00429871
- Locations
- 🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷Air Forces Military Hospital of Athens, Athens, Greece
🇬🇷401 Military Hospital of Athens, Athens, Greece
Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer
- Conditions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 800
- Registration Number
- NCT00427713
- Locations
- 🇬🇧
Wansbeck General Hospital, Ashington, England, United Kingdom
🇬🇧Good Hope Hospital, Birmingham, England, United Kingdom
🇬🇧Furness General Hospital, Barrow in Furness, England, United Kingdom
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- First Posted Date
- 2007-01-23
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Royal Liverpool University Hospital
- Target Recruit Count
- 1110
- Registration Number
- NCT00425360
- Locations
- 🇬🇧
Pilgrim Hospital, Boston, England, United Kingdom
🇬🇧Bristol Haematology and Oncology Centre, Bristol, England, United Kingdom
🇬🇧Dorset County Hospital, Dorchester, England, United Kingdom
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 145
- Registration Number
- NCT00423696
- Locations
- 🇫🇷
C.H.U. de Brest, Brest, France
🇫🇷Centre Regional Francois Baclesse, Caen, France
🇫🇷Centre Oscar Lambret, Lille, France
Standard Versus Continuous Capecitabine in Advanced Breast Cancer
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hospital San Carlos, Madrid
- Target Recruit Count
- 195
- Registration Number
- NCT00418028
- Locations
- 🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
- Conditions
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 408
- Registration Number
- NCT00417209
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2014-09-03
- Lead Sponsor
- Herbert Hurwitz, MD
- Target Recruit Count
- 50
- Registration Number
- NCT00416494
Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer
- Conditions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2007-02-13
- Lead Sponsor
- Georgia Center for Oncology Research & Education
- Target Recruit Count
- 100
- Registration Number
- NCT00415285
- Locations
- 🇺🇸
Emory Crawford Long Hospital, Atlanta, Georgia, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Grady Memorial Hospital, Atlanta, Georgia, United States
Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2019-07-25
- Target Recruit Count
- 18
- Registration Number
- NCT00414271
- Locations
- 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.